RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a One-Time infusion of Dual-Target CAR-T cells outsmart resistant blood cancers?
⭐️ CURE ⭐️ Not yet recruitingThis phase 1 trial is testing an experimental therapy called CD19/CD20 dual-target in vivo CAR-T for people with relapsed or refractory B-cell malignancies—blood cancers that have not responded to standard treatments. The approach uses a lentiviral product to engineer a patient's…
Matched conditions: RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: ⭐️ CURE ⭐️
Last updated Aug 15, 2026 00:00 UTC
-
Experimental CAR T-Cell therapy targets tough lymphoma
Disease control Not yet recruitingThis early-phase trial tests a new type of immune cell therapy called GoFast CD19 CAR T-cells in 9 adults with relapsed or refractory large B-cell lymphoma. Participants receive chemotherapy followed by an infusion of their own modified immune cells. The study aims to see if the …
Matched conditions: RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Chinese PLA General Hospital • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC